SCHEMBL200320

SCHEMBL200320

N#CCc1ccc(CBr)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.43
ALDH1A1 P00352 1/20 0.43
TSHR P16473 1/20 0.43
KMT2A Q03164 2/20 0.40
KDM4E B2RXH2 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
CYP1A1 P04798 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP1B1 Q16678 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
ENPP2 Q13822 1/20 0.36
TNF P01375 1/20 0.36
CES2 O00748 1/20 0.35
CES1 P23141 1/20 0.35
PKM P14618 2/20 0.35
MMP3 P08254 1/20 0.34
NPC1 O15118 2/20 0.34
LMNA P02545 1/20 0.34
MAPT P10636 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2154504 0.86 KMT2A (0.47) KMT2AKDM4ETDP1CYP1A1CYP1A2
SCHEMBL10534013 0.85 ENPP2 (0.49) TRPA1ALDH1A1TSHRKMT2AKDM4E
SCHEMBL11547944 0.80 TDP1 (0.48) KMT2AKDM4ETDP1CYP1A1CYP1A2
SCHEMBL28387994 0.79 KDM4E (0.43) TRPA1ALDH1A1TSHRKMT2AKDM4E
SCHEMBL1875 0.79 MAOB (0.42) KMT2AKDM4ETDP1CYP1A1CYP1A2
SCHEMBL23137321 0.78 MMP3 (0.50) TSHRKMT2AKDM4ETDP1L3MBTL1
SCHEMBL196175 0.78 MMP3 (0.50) TSHRKMT2AKDM4ETDP1L3MBTL1
SCHEMBL8763328 0.78 KMT2A (0.42) ALDH1A1TSHRKMT2AKDM4ETDP1
SCHEMBL7489893 0.77 MAOB (0.41) KMT2AKDM4ETDP1CYP1A1CYP1A2
SCHEMBL2944694 0.77 ENPP2 (0.53) TRPA1ALDH1A1TSHRKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250325687-A1 CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST MABSOFT THERAPEUTICS SHANGHAI CO LTD (CN) 2025-10-23 US disclosed
EP-4561993-A1 INHIBITORS OF PLASMA KALLIKREIN Rezolute, Inc. (US) 2025-06-04 EP disclosed
CN-120051460-A Plasma kallikrein inhibitors 瑞泽路特有限公司 2025-05-27 CN disclosed
EP-4508061-A1 CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST Mabsoft Therapeutics (Shanghai) Co., Ltd. (CN) 2025-02-19 EP disclosed
CN-119365479-A Conjugates comprising Toll-like receptor agonists 慕宝盛科生物医药(上海)有限公司 2025-01-24 CN disclosed
WO-2024025907-A1 INHIBITORS OF PLASMA KALLIKREIN REZOLUTE, INC. (US) 2024-02-01 WO disclosed
WO-2023198195-A1 CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST MABSOFT THERAPEUTICS (SHANGHAI) CO., LTD. (CN) 2023-10-19 WO disclosed
CN-111655700-B Oxadiazolopyridine derivatives as ghrelin O-acyltransferase (GOAT) inhibitors 勃林格殷格翰国际有限公司 2023-07-18 CN disclosed
EP-3746451-B1 BENZYL-, (PYRIDIN-3-YL)METHYL- OR (PYRIDIN-4-YL)METHYL-SUBSTITUTED OXADIAZOLOPYRIDINE DERIVATIVES AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2023-07-12 EP disclosed
EP-3746451-B1 BENZYL-, (PYRIDIN-3-YL)METHYL- OR (PYRIDIN-4-YL)METHYL-SUBSTITUTED OXADIAZOLOPYRIDINE DERIVATIVES AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2023-07-12 EP disclosed
WO-2000037432-A1 METHOD OF PRODUCING AROMATIC HALOGEN METHYL COMPOUNDS BAYER AKTIENGESELLSCHAFT (DE) 2000-06-29 WO disclosed
WO-1999020275-A1 THERAPEUTIC USES OF QUINOLINE DERIVATIVES AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 1999-04-29 WO disclosed
EP-0315399-B1 Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same RHONE POULENC RORER INT (US) 1996-01-10 EP disclosed
EP-0393534-B1 Pharmaceutically active pteridine derivatives ROEHM GMBH (DE) 1995-07-12 EP disclosed
US-5124326-A Antiarrhythmic, hypotensive agents; diuretics ROEHM GMBH CHEMISCHE FABRIK (DE) 1992-06-23 US disclosed
US-5059610-A QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1991-10-22 US disclosed
EP-0393534-A2 Pharmaceutically active pteridine derivatives RÖHM GMBH (DE) 1990-10-24 EP disclosed
US-4920132-A Quinoline derivatives and use thereof as antagonists of leukotriene D4 RORER PHARMACEUTICAL CORP. (US) 1990-04-24 US disclosed
WO-1989004305-A1 QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D4 RORER INTERNATIONAL (OVERSEAS) INC. (US) 1989-05-18 WO disclosed
EP-0315399-A2 Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) 1989-05-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250325687-A1 CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST TLR3, TLR7, TLR8 TRPA1 1922/4885ALDH1A1 3336/4885TSHR 304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.